<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39329380</PMID><DateCompleted><Year>2024</Year><Month>12</Month><Day>16</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>24</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>68</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Jan</Month><Day>01</Day></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>Clinicopathological Characteristics and Outcomes of Colorectal Cancer With Heterogenous Staining of Mismatch Repair Protein.</ArticleTitle><Pagination><StartPage>48</StartPage><EndPage>59</EndPage><MedlinePgn>48-59</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000003527</ELocationID><Abstract><AbstractText Label="BACKGROUND">Scant data are available on heterogenous staining of mismatch repair protein in colorectal cancer.</AbstractText><AbstractText Label="OBJECTIVE">This study aimed to improve insights into clinicopathologic features and prognosis of colorectal cancer harboring heterogenous mismatch repair protein staining.</AbstractText><AbstractText Label="DESIGN">A single-center retrospective observational study.</AbstractText><AbstractText Label="SETTING">This study was conducted in a tertiary referral center in China between 2014 and 2018.</AbstractText><AbstractText Label="PATIENTS">Patients with colorectal cancers with heterogenous staining of mismatch repair protein were included.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES">Clinicopathologic and molecular features and survival outcomes were analyzed.</AbstractText><AbstractText Label="RESULTS">A total of 151 of 6721 colorectal cancers (2.2%) exhibited heterogenous staining for at least 1 mismatch repair protein, with intraglandular heterogeneity being the most common pattern (89.4%). Heterogenous mutL homolog 1 staining was significantly associated with distant metastasis ( p = 0.03), whereas heterogenous mutS homolog 2 staining was associated with left-sided ( p = 0.03) and earlier pT stage tumors ( p = 0.02). The rates of microsatellite instability-high, K -ras and BRAF mutation were 12.6%, 47.3%, and 3.4%, respectively. Microsatellite instability-high was significantly associated with higher intraglandular mutS homolog 6 heterogeneity frequency ( p &lt; 0.001) and decreased mutS homolog 6 expression level (&lt;27.5%, p = 0.01). BRAF mutation was associated with the coexistence of intraglandular and clonal heterogeneity ( p = 0.003) and decreased PMS1 homolog 2 expression level ( p = 0.01). Multivariable analysis revealed that progression-free survival was significantly associated with tumor stage ( p = 0.003), stroma fraction ( p = 0.004), and heterogenous PMS1 homolog 2 staining ( p = 0.02). Overall survival was linked to tumor stage ( p = 0.006) and BRAF mutation ( p = 0.01).</AbstractText><AbstractText Label="LIMITATIONS">The limitations of this study include the absence of testing for mutL homolog 1 promoter methylation and mismatch repair gene mutations, its retrospective design, and insufficient data related to direct comparison with deficient mismatch repair and proficient mismatch repair colorectal cancer.</AbstractText><AbstractText Label="CONCLUSIONS">Heterogenous mismatch repair protein staining in colorectal cancer exhibits distinct associations with tumor location, stage, microsatellite instability, BRAF mutation, and prognosis. It is recommended to report mutS homolog 6 heterogeneity as it may indicate microsatellite instability-high. See Video Abstract .</AbstractText><AbstractText Label="RESULTADOS Y CARACTERSTICAS CLNICOPATOLGICAS EN LA TINCIN HETEROGNEA DE PROTENAS REPARADORAS DE ERROR DE EMPAREJAMIENTO EN CASOS DE CNCER COLORRECTAL">ANTECEDENTES:Son pocos los datos disponibles sobre la tinci&#xf3;n heterog&#xe9;nea de la prote&#xed;na reparadora de errores de emparejamiento en casos de c&#xe1;ncer colorrectal.OBJETIVO:Este estudio tuvo como objetivo el mejorar los conocimientos sobre las caracter&#xed;sticas cl&#xed;nico-patol&#xf3;gicas y el pron&#xf3;stico del c&#xe1;ncer colorrectal que alberga tinci&#xf3;n heterog&#xe9;nea de prote&#xed;nas reparadoras del emparejamiento.DISE&#xd1;O:Estudio observacional retrospectivo y unic&#xe9;ntrico.&#xc1;MBITO:El presente estudio fu&#xe9; realizado en un centro de referencia terciario en China entre 2014 y 2018.PACIENTES:Se incluyeron c&#xe1;nceres colorrectales con tinci&#xf3;n heterog&#xe9;nea de la prote&#xed;na reparadora de errores de emparejamiento.PRINCIPALES MEDIDAS DE RESULTADOS:Se analizaron las caracter&#xed;sticas cl&#xed;nico-patol&#xf3;gicas y moleculares como tambi&#xe9;n los resultados de la sobrevida.RESULTADOS:Un total de 151 de 6721 c&#xe1;nceres colorrectales (2,2%) exhibieron tinci&#xf3;n heterog&#xe9;nea para al menos una prote&#xed;na reparadora de error de emparejamiento, siendo la h&#xe9;terogenicidad intraglandular el patr&#xf3;n m&#xe1;s com&#xfa;n (89,4%).La tinci&#xf3;n heterog&#xe9;nea de MLH1 se asoci&#xf3; significativamente con met&#xe1;stasis a distancia (p = 0,03), mientras que la tinci&#xf3;n heterog&#xe9;nea de MSH2 se asoci&#xf3; con tumores del lado izquierdo (p = 0,03) y en casos de estad&#xed;o pT anterior (p = 0,02). Las tasas de inestabilidad alta de microsat&#xe9;lites, la mutaci&#xf3;n KRAS y BRAF fueron del 12,6%, 47,3% y 3,4%, respectivamente.La inestabilidad alta de microsat&#xe9;lites se asoci&#xf3; significativamente con una mayor frecuencia de heterogenicidad intraglandular de MSH6 (p &lt;0,001) y una disminuci&#xf3;n del nivel de expresi&#xf3;n de MSH6 (&lt;27,5%) (P = 0,01). La mutaci&#xf3;n BRAF se asoci&#xf3; con la coexistencia de heterogenicidad intraglandular y clonal (p = 0,003) y una disminuci&#xf3;n del nivel de expresi&#xf3;n de PMS2 (p = 0,01).El an&#xe1;lisis multivariable revel&#xf3; que la sobrevida libre de progresi&#xf3;n se asoci&#xf3; significativamente con el estadio del tumor (p = 0,003), la fracci&#xf3;n del estroma (p = 0,004) y la tinci&#xf3;n heterog&#xe9;nea de PMS2 (p = 0,02). La sobrevida general estuvo relacionada con el estadio del tumor (p = 0,006) y la mutaci&#xf3;n BRAF (p = 0,01).LIMITACIONES:Las limitaciones del presente estudio incluyen la ausencia de pruebas para la metilaci&#xf3;n del promotor MLH1 y las mutaciones del gen de reparaci&#xf3;n de errores de coincidencia. Tambi&#xe9;n se incluye el dise&#xf1;o retrospectivo y los datos insuficientes relacionados con la comparaci&#xf3;n directa de la reparaci&#xf3;n deficiente de errores de emparejamiento y los casos de c&#xe1;ncer colorrectal competente en la reparaci&#xf3;n de errores de emparejamiento.CONCLUSIONES:La tinci&#xf3;n de prote&#xed;nas reparadoras de errores de emparejamiento en casos de c&#xe1;ncer colorrectal exhibe asociaciones distintas con la localizaci&#xf3;n y el estad&#xed;o del tumor, la inestabilidad de los microsat&#xe9;lites, la mutaci&#xf3;n BRAF y el pron&#xf3;stico. Se recomienda informar de la heterogenicidad de MSH6, ya que puede indicar una inestabilidad alta de los microsat&#xe9;lites. (Traducci&#xf3;n-Dr. Xavier Delgadillo ).</AbstractText><CopyrightInformation>Copyright &#xa9; The ASCRS 2024.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Xian</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Pathology, West China Hospital, Sichuan University, Chengdu, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology and Sichuan University-University of Oxford Huaxi Joint Centre for Gastrointestinal Cancer, West China Hospital, Sichuan University, Chengdu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yu-Jue</ForeName><Initials>YJ</Initials><AffiliationInfo><Affiliation>Department of Pathology, West China Hospital, Sichuan University, Chengdu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Lin-Yong</ForeName><Initials>LY</Initials><AffiliationInfo><Affiliation>Department of Pathology, West China Hospital, Sichuan University, Chengdu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tu</LastName><ForeName>Yin-Xia</ForeName><Initials>YX</Initials><AffiliationInfo><Affiliation>Department of Pathology, West China Hospital, Sichuan University, Chengdu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yue</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Pathology, West China Hospital, Sichuan University, Chengdu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Dan</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-9187-7152</Identifier><AffiliationInfo><Affiliation>Department of Pathology, West China Hospital, Sichuan University, Chengdu, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology and Sichuan University-University of Oxford Huaxi Joint Centre for Gastrointestinal Cancer, West China Hospital, Sichuan University, Chengdu, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>No. ZYA124059</GrantID><Agency>The 1&#xc2;&#xb7;3&#xc2;&#xb7;5 project for disciplines of excellence, West China Hospital, Sichuan University</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="C482119">BRAF protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C117307">KRAS protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C501486">MLH1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.1.3</RegistryNumber><NameOfSubstance UI="C497172">MSH2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.1.3</RegistryNumber><NameOfSubstance UI="D000070957">MutL Protein Homolog 1</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.1.3</RegistryNumber><NameOfSubstance UI="D051718">MutS Homolog 2 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D048493">Proto-Oncogene Proteins B-raf</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.5.2</RegistryNumber><NameOfSubstance UI="D016283">Proto-Oncogene Proteins p21(ras)</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014408" MajorTopicYN="N">Biomarkers, Tumor</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002681" MajorTopicYN="N" Type="Geographic">China</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015179" MajorTopicYN="Y">Colorectal Neoplasms</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053843" MajorTopicYN="Y">DNA Mismatch Repair</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053842" MajorTopicYN="Y">Microsatellite Instability</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000070957" MajorTopicYN="N">MutL Protein Homolog 1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051718" MajorTopicYN="N">MutS Homolog 2 Protein</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009367" MajorTopicYN="N">Neoplasm Staging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D048493" MajorTopicYN="N">Proto-Oncogene Proteins B-raf</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016283" MajorTopicYN="N">Proto-Oncogene Proteins p21(ras)</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>12</Month><Day>16</Day><Hour>12</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>27</Day><Hour>16</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>27</Day><Hour>8</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39329380</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000003527</ArticleId><ArticleId IdType="pii">00003453-990000000-00759</ArticleId></ArticleIdList><ReferenceList><Title/><Reference><Citation>Jiang M, Jia K, Wang L, et al. Alterations of DNA damage response pathway: biomarker and therapeutic strategy for cancer immunotherapy. Acta Pharm Sin B. 2021;11:2983&#x2013;2994.</Citation></Reference><Reference><Citation>Jin Z, Sinicrope FA. Mismatch repair-deficient colorectal cancer: building on checkpoint blockade. J Clin Oncol. 2022;40:2735&#x2013;2750.</Citation></Reference><Reference><Citation>Alwers E, Jia M, Kloor M, Bl&#xe4;ker H, Brenner H, Hoffmeister M. Associations between molecular classifications of colorectal cancer and patient survival: a systematic review. Clin Gastroenterol Hepatol. 2019;17:402&#x2013;410.e2.</Citation></Reference><Reference><Citation>Jin Z, Sinicrope FA. Prognostic and predictive values of mismatch repair deficiency in non-metastatic colorectal cancer. Cancers (Basel). 2021;13:300.</Citation></Reference><Reference><Citation>Lindor NM, Burgart LJ, Leontovich O, et al. Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors. J Clin Oncol. 2002;20:1043&#x2013;1048.</Citation></Reference><Reference><Citation>Matsubayashi H, Oishi T, Sasaki K, et al. Discordance of microsatellite instability and mismatch repair immunochemistry occurs depending on the cancer type. Hum Pathol. 2023;135:54&#x2013;64.</Citation></Reference><Reference><Citation>Chen W, Frankel WL. A practical guide to biomarkers for the evaluation of colorectal cancer. Mod Pathol. 2019;32:1&#x2013;15.</Citation></Reference><Reference><Citation>Joost P, Veurink N, Holck S, et al. Heterogenous mismatch-repair status in colorectal cancer. Diagn Pathol. 2014;9:126.</Citation></Reference><Reference><Citation>McCarthy AJ, Capo-Chichi JM, Spence T, et al. Heterogenous loss of mismatch repair (MMR) protein expression: a challenge for immunohistochemical interpretation and microsatellite instability (MSI) evaluation. J Pathol Clin Res. 2019;5:115&#x2013;129.</Citation></Reference><Reference><Citation>Wang C, Zhang L, Vakiani E, Shia J. Detecting mismatch repair deficiency in solid neoplasms: immunohistochemistry, microsatellite instability, or both? Mod Pathol. 2022;35:1515&#x2013;1528.</Citation></Reference><Reference><Citation>Jiang H, Zhou Y, Lin Y, Chan RCK, Liu J, Chen H. Deep learning for computational cytology: a survey. Med Image Anal. 2023;84:102691.</Citation></Reference><Reference><Citation>Eriksen AC, S&#xf8;rensen FB, Lindebjerg J, et al. The prognostic value of tumor-infiltrating lymphocytes in stage II colon cancer. A nationwide population-based study. Transl Oncol. 2018;11:979&#x2013;987.</Citation></Reference><Reference><Citation>Eriksen AC, Andersen JB, Kristensson M, et al. Computer-assisted stereology and automated image analysis for quantification of tumor infiltrating lymphocytes in colon cancer. Diagn Pathol. 2017;12:65.</Citation></Reference><Reference><Citation>Amin MB, Greene FL, Edge SB, et al. The Eighth Edition AJCC Cancer Staging Manual: continuing to build a bridge from a population-based to a more &#x201c;personalized&#x201d; approach to cancer staging. CA Cancer J Clin. 2017;67:93&#x2013;99.</Citation></Reference><Reference><Citation>Nagtegaal ID, Odze RD, Klimstra D, et al.; WHO Classification of Tumours Editorial Board. The 2019 WHO classification of tumours of the digestive system. Histopathology. 2020;76:182&#x2013;188.</Citation></Reference><Reference><Citation>Jiang D, Shu C, Zhang W, et al. Low level of microsatellite instability correlates with short disease-free survival of gastric cancer patients undergoing neoadjuvant chemotherapy. Virchows Arch. 2021;478:231&#x2013;240.</Citation></Reference><Reference><Citation>Jiang D, Hveem TS, Glaire M, et al. Automated assessment of CD8(+) T-lymphocytes and stroma fractions complement conventional staging of colorectal cancer. EBioMedicine. 2021;71:103547.</Citation></Reference><Reference><Citation>Graham RP, Kerr SE, Butz ML, et al. Heterogenous MSH6 loss is a result of microsatellite instability within MSH6 and occurs in sporadic and hereditary colorectal and endometrial carcinomas. Am J Surg Pathol. 2015;39:1370&#x2013;1376.</Citation></Reference><Reference><Citation>Hechtman JF, Rana S, Middha S, et al. Retained mismatch repair protein expression occurs in approximately 6% of microsatellite instability-high cancers and is associated with missense mutations in mismatch repair genes. Mod Pathol. 2020;33:871&#x2013;879.</Citation></Reference><Reference><Citation>Sarode VR, Robinson L. Screening for lynch syndrome by immunohistochemistry of mismatch repair proteins: significance of indeterminate result and correlation with mutational studies. Arch Pathol Lab Med. 2019;143:1225&#x2013;1233.</Citation></Reference><Reference><Citation>Mangold E, Pagenstecher C, Friedl W, et al. Tumours from MSH2 mutation carriers show loss of MSH2 expression but many tumours from MLH1 mutation carriers exhibit weak positive MLH1 staining. J Pathol. 2005;207:385&#x2013;395.</Citation></Reference><Reference><Citation>Chen W, Pearlman R, Hampel H, et al. MSH6 immunohistochemical heterogeneity in colorectal cancer: comparative sequencing from different tumor areas. Hum Pathol. 2020;96:104&#x2013;111.</Citation></Reference><Reference><Citation>Zhang J, Zhang X, Wang Q, et al. Histomorphological and molecular genetic characterization of different intratumoral regions and matched metastatic lymph nodes of colorectal cancer with heterogenous mismatch repair protein expression. J Cancer Res Clin Oncol. 2023;149:3423&#x2013;3434.</Citation></Reference><Reference><Citation>Den&#x10d;i&#x107; T, Petrovi&#x107; A, Jovi&#x10d;i&#x107; Milentijevi&#x107; M, et al. The importance of immunohistochemical heterogeneous expression of MMR protein in patients with colorectal cancer in stage II and III of the disease. Medicina (Kaunas). 2023;59:489.</Citation></Reference><Reference><Citation>Berrino E, Aquilano MC, Valtorta E, et al. Unique patterns of heterogeneous mismatch repair protein expression in colorectal cancer unveil different degrees of tumor mutational burden and distinct tumor microenvironment features. Mod Pathol. 2023;36:100012.</Citation></Reference><Reference><Citation>Barrow E, Jagger E, Brierley J, et al. Semiquantitative assessment of immunohistochemistry for mismatch repair proteins in Lynch syndrome. Histopathology. 2010;56:331&#x2013;344.</Citation></Reference><Reference><Citation>Singh N, Wong R, Tchrakian N, et al. Interpretation and reporting terminology for mismatch repair protein immunohistochemistry in endometrial cancer. The British Association of Gynaecological Pathologists (BAGP)Guidance Document. Version 1.1 June 2020. Available at https://www.thebagp.org/wp-content/uploads/download-manager-files/1593411202wpdm_BAGP%20MMR%20IHC%20Interpretation%20June%202020.pdf .</Citation></Reference><Reference><Citation>Stelloo E, Jansen AML, Osse EM, et al. Practical guidance for mismatch repair-deficiency testing in endometrial cancer. Ann Oncol. 2017;28:96&#x2013;102.</Citation></Reference><Reference><Citation>Guo TA, Wu YC, Tan C, et al. Clinicopathologic features and prognostic value of KRAS, NRAS and BRAF mutations and DNA mismatch repair status: a single-center retrospective study of 1,834 Chinese patients with stage I-IV colorectal cancer. Int J Cancer. 2019;145:1625&#x2013;1634.</Citation></Reference><Reference><Citation>Phipps AI, Scoggins J, Rossing MA, Li CI, Newcomb PA. Temporal trends in incidence and mortality rates for colorectal cancer by tumor location: 1975&#x2013;2007. Am J Public Health. 2012;102:1791&#x2013;1797.</Citation></Reference><Reference><Citation>Missiaglia E, Jacobs B, D&#x2019;Ario G, et al. Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features. Ann Oncol. 2014;25:1995&#x2013;2001.</Citation></Reference><Reference><Citation>Taieb J, Kourie HR, Emile JF, et al.; Pan-European Trials in Alimentary Tract Cancer (PETACC)-8 Investigators. Association of prognostic value of primary tumor location in stage III colon cancer with RAS and BRAF mutational status. JAMA Oncol. 2018;4:e173695.</Citation></Reference><Reference><Citation>Guo L, Wang Y, Yang W, et al. Molecular profiling provides clinical insights into targeted and immunotherapies as well as colorectal cancer prognosis. Gastroenterology. 2023;165:414&#x2013;428.e7.</Citation></Reference><Reference><Citation>Xu W, He Y, Wang Y, et al. Risk factors and risk prediction models for colorectal cancer metastasis and recurrence: an umbrella review of systematic reviews and meta-analyses of observational studies. BMC Med. 2020;18:172.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>